Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells. By ...
Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 4 clinical study ...
On-time osteoporosis treatments are vital for reaping their full prevention benefits, according to a new study. In a study of 2,594 adults initiating denosumab for non-cancer indications (Prolia), ...
Dear Dr. Roach: I am a 67-year-old woman who has been diagnosed with osteoporosis, currently treated with Prolia injections. I also previously took Fosamax for four years. I must have a tooth ...
--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...
Subjects treated for 10 years with denosumab achieved an average cumulative 10-year gain in BMD of 21.7 percent at the lumbar spine and 9.2 percent at the total hip, compared to baseline in the ...
Prolia should be covered by Medicare Part A, Part B, or Part D, depending on why you need to take the drug and whether you will administer it yourself. Prolia (denosumab) is an injectable monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback